All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0822-YF9036 | TS-Fluc Anti-Human Glypican 2 scFv (XW-462) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-462 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9037 | TS-Fluc Anti-Human Glypican 2 scFv (XW-463) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-463 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9445 | TS-Fluc Anti-Human Glypican 2 scFv (XW-462) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-462 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9446 | TS-Fluc Anti-Human Glypican 2 scFv (XW-463) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-463 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF9854 | TS-IL15 SA Anti-Human Glypican 2 scFv (XW-462) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-462 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF9855 | TS-IL15 SA Anti-Human Glypican 2 scFv (XW-463) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-463 | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
XS-0822-YF10263 | TS-IL15 SA Anti-Human Glypican 2 scFv (XW-462) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-462 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10264 | TS-IL15 SA Anti-Human Glypican 2 scFv (XW-463) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-463 | Human | 7H-YB-IL15 SA-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10672 | TS-IL15 SA Anti-Human Glypican 2 scFv (XW-462) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-462 | Mouse | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-0822-YF10673 | TS-IL15 SA Anti-Human Glypican 2 scFv (XW-463) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-463 | Human | 7H-YB-IL15 SA-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
XS-1122-YF3222 | Anti-Glypican 2 TCR-ABR (scFv-CD3γ, XW-462) CAR Plasmid, pCDCAR1 | Human | XW-462 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
XS-1122-YF3223 | Anti-Glypican 2 TCR-ABR (scFv-CD3γ, XW-463) CAR Plasmid, pCDCAR1 | Human | XW-463 | Human | scFv-CD3γ | Lentiviral vector | T Cell | ||
XS-1122-YF4142 | Anti-Glypican 2 TCR-ABR (scFv-CD3δ, XW-462) CAR Plasmid, pCDCAR1 | Human | XW-462 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
XS-1122-YF4143 | Anti-Glypican 2 TCR-ABR (scFv-CD3δ, XW-463) CAR Plasmid, pCDCAR1 | Human | XW-463 | Human | scFv-CD3δ | Lentiviral vector | T Cell | ||
XS-1122-YF5062 | Anti-Glypican 2 TCR-ABR (scFv-CD3ε, XW-462) CAR Plasmid, pCDCAR1 | Human | XW-462 | Mouse | scFv-CD3ε | Lentiviral vector | T Cell | ||
XS-1122-YF5063 | Anti-Glypican 2 TCR-ABR (scFv-CD3ε, XW-463) CAR Plasmid, pCDCAR1 | Human | XW-463 | Human | scFv-CD3ε | Lentiviral vector | T Cell | ||
XS-1122-YF5982 | Anti-Glypican 2 (XW-462) h(CD28-CD3ζ) CAR, pAAV | Human | XW-462 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
XS-1122-YF5983 | Anti-Glypican 2 (XW-463) h(CD28-CD3ζ) CAR, pAAV | Human | XW-463 | Human | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
XS-1122-YF6902 | Anti-Glypican 2 (XW-462) h(41BB-CD3ζ) CAR, pAAV | Human | XW-462 | Mouse | scFv-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
XS-1122-YF6903 | Anti-Glypican 2 (XW-463) h(41BB-CD3ζ) CAR, pAAV | Human | XW-463 | Human | scFv-41BB-CD3ζ | Adeno-associated viral (AAV) vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION